期刊
NANOMEDICINE
卷 8, 期 5, 页码 687-698出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.12.134
关键词
cisplatin; combination chemotherapy; irinotecan; nanoparticle; PSMA
资金
- Koch-Prostate Cancer Foundation Award in Nanotherapeutics
- NCI Center of Cancer Nanotechnology Excellence at MIT-Harvard [U54-CA151884]
- NSF graduate research fellowship
- NDSEG graduate research fellowship
Aim: Two unexplored aspects for irinotecan and cisplatin (I&C)combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. Materials & methods: Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据